TTP plc and Expedeon extend partnership to develop rapid point-of-care diagnostics
June 13th, 2017
Innova to continue to provide custom bioconjugation services to support TTP’s Desktop Biology initiative
Cambridge, UK, 13 June 2017: TTP plc, Europe’s leading technology and product development company, today announces its ongoing partnership with Expedeon (Innova), a specialist provider of bioconjugation products and services, to enable its rapid point-of-care diagnostics development program.
TTP’s Desktop Biology provides fast track development and rapid route to market for companies looking to commercialise their assays. Innova is providing custom magnetic beads and alkaline phosphatase conjugation services, to support the conjugate screening phases of TTP’s assay development.
The original custom project, under which Innova developed magnetic bead conjugation previously not offered either off-the-shelf or as a custom service, involved developing a range of magnetic beads of different diameters conjugated to capture antibodies. Innova produced all conjugates within 1 week of receiving antibody material. Following the success of this initial project the companies are planning to continue to collaborate, to offer a seamless approach for companies looking to accelerate the development of their diagnostic or research assays.
The relationship with Expedeon will further strengthen the services TTP provides to its customers by innovating and expanding its offering of new diagnostic systems to the market.
Nick Gee, CEO and CSO at Expedeon, commented: “We are pleased to be supporting TTP in the development of point-of-care diagnostics. The immunodiagnostics market continues to expand worldwide, and this therefore presents an exciting opportunity for both Innova and TTP.”
Edwin Stone, at TTP plc, said: “By offering a full-service assay and hardware development solution, TTP is able to provide its clients with greatly reduced time to market. Our relationship with Innova expands and reinforces our Desktop Biology service, enabling our clients to achieve a competitive advantage.”
About TTP plc
TTP has been developing cutting edge technologies for the Life Science industry for 3 decades. Our scientists and engineers inhabit the fascinating and endlessly changing intersection between physics, engineering and the biological sciences, spotting opportunities to create new technologies and tools for the advancement of this exciting field.
TTP’s focus areas include: bioprocess (manufacture based on living cells or cell products), human and animal diagnostics, biosensors, and instrumentation for molecular biology and pharmaceutical applications.
In addition to Life Science TTP also creates disruptive products based on advances in technology and engineering innovation. TTP’s technology lies behind many products and processes in areas as diverse as communications, digital printing, instrumentation, consumer and industrial products, medical devices, cleantech and security systems.
About Expedeon Limited
Expedeon are world leading experts in easy-to-use, cutting-edge bioconjugation technologies and services. The Company has the flexibility to support scientists from academia through to commercial manufacturing, developing and supplying reagent products to make science easier, both off-the shelf and to customer specification. Innova’s products are based on its antibody and protein labelling technology, nanoparticle and oligonucleotide labelling and phosphate detection enzyme assay technologies.
All of Expedeon’ product ranges are of the highest quality and are designed to streamline R&D and manufacturing processes, whilst also reducing overall project costs by cutting expenses associated with e.g. material waste, in-house equipment and staff time, providing increased return on investment compared to traditional methods.
Expedeon’ ever expanding portfolio, including the Lightning-Link®, InnovaCoat® and Thunder-Link® brands, is available to research laboratories, pharmaceutical, biotechnology and diagnostic companies worldwide.
Expedeon is a privately held company and was founded in 2002.